Story perspectives

Rice Bran Compound Boosts Quality of Life in Cancer Patients

4/1/2026

Summary

Story summary

In New South Wales, Australia, a randomized trial tested rice bran arabinoxylan compound (RBAC) in 29 cancer patients under systemic treatment.
The RBAC group showed better global quality of life and improved role and social functioning versus placebo.
They also experienced less fatigue, pain, dyspnoea, and appetite loss.
Elevations in cytokines in the RBAC group suggest a link between immune activity and quality of life; no adverse events were reported.

1 of 1

Story summary

In New South Wales, Australia, a randomized trial tested rice bran arabinoxylan compound (RBAC) in 29 cancer patients under systemic treatment.
The RBAC group showed better global quality of life and improved role and social functioning versus placebo.
They also experienced less fatigue, pain, dyspnoea, and appetite loss.
Elevations in cytokines in the RBAC group suggest a link between immune activity and quality of life; no adverse events were reported.